

# ENHANCED PROCESS CONTROL FOR LIPID-BASED NANOPARTICLES: LNPS AND LIPOSOMES

In this article, Antonio Costa, PhD, Chief Executive Officer of DIANT Pharma, discusses the use of lipid nanoparticles in the modern drug delivery industry and introduces the DIANT system for the continuous processing of nanoparticles with integrated process analytical technology, which can provide the quality required for these injectable, complex formulations.

## INTRODUCTION

Nanoparticles are once again in the spotlight, this time as a critical tool to combat the spread of covid-19. In particular, messenger ribonucleic acid (mRNA) encapsulated in lipid nanoparticles (LNPs) has been successfully manufactured, distributed and administered to populations worldwide. The high efficacy and strong protection of covid-19 mRNA-LNP vaccines has generated significant interest in them as a candidate for future vaccines and therapeutics. However, information released by the European Medicines Agency (EMA) covid-19 data leak emphasises the need to better understand quality issues observed in the LNP manufacturing process – for example, quality issues may be traced to RNA instability and LNP particle size.

## mRNA-LNPS

The components of mRNA-LNPs can be divided into four main groups:

1. An ionisable, cationic lipid
2. One or more neutral/structural lipids
3. mRNA
4. Buffering systems and water.

All of these components come together to form a sophisticated and tunable delivery system. In this case, the delivery cargo is mRNA and the target delivery location is a specific tissue or cell type. There is a truly remarkable relationship between all of these components that have made LNPs a success story. To start, the mRNA, which has a particular sequence of nucleotides, is processed by ribosomes to synthesise a protein, such as a spike protein.

The ionisable, cationic lipid has multiple roles, such as promoting the encapsulation of mRNA during the LNP synthesis

process and releasing the mRNA within the cytoplasm. The neutral/structure lipids, such as distearoylphosphatidylcholine (DSPC) and cholesterol, provide the general framework or structure of the particles, whereas pegylated lipids coat the surface of the LNPs and provide physical stability and enable longer circulation times in the host.

Buffering systems are important for properly forming and neutralising the particles. Additionally, water, a sometimes-overlooked component, is very important in the core structure of the LNP, providing a continuum of hydrogen bonds between the mRNA and the hydrophilic portions of the lipid components. Accordingly, the LNP formulation is a critical factor linked directly to RNA encapsulation and multiple aspects of the delivery system's overall pharmacokinetics and pharmacodynamics, including the localised target tissue or cellular expression.

## LIPOSOMES

Liposomal nanoparticles have been approved as drug products throughout the world for a variety of clinical indications,

“Liposomal nanoparticles have been approved as drug products throughout the world for a variety of clinical indications, including cancer and fungal treatments, with the highest percentage of liposomal drug products being anti-cancer therapies.”



**Dr Antonio Costa**  
Chief Executive Officer  
E: [costa@diantpharma.com](mailto:costa@diantpharma.com)



**DIANT Pharma**  
1392 Storrs Road  
Unit 4213 Room 108  
Storrs  
CT 06269-4213  
United States

[www.diantpharma.com](http://www.diantpharma.com)

“Although these therapeutics are very beneficial to patients, scalable processing and manufacturing technology platforms are still being developed.”

including cancer and fungal treatments, with the highest percentage of liposomal drug products being anti-cancer therapies. The APIs in these drug products are typically small molecules such as doxorubicin, daunorubicin, cytarabine or irinotecan.

The basic principle of how liposomes are effective is that they deliver a high payload directly to the site of action, such as a tumour, resulting in a more efficacious and safer drug product. In brief, liposomes consist of a lipid bilayer that surrounds an aqueous compartment. The majority of liposomes that have been approved by regulatory agencies have lipid compositions that include phosphatidylcholine lipids, cholesterol and either a PEGylated or charged lipid.

The composition of the lipid bilayer plays a major role in the liposome’s stability, both in storage and *in vivo* conditions, meaning that the type of lipids and their molar ratios are considered critical material attributes. For example, cholesterol is known to affect bilayer rigidity and PEGylated lipids promote steric stabilisation of the bilayer. The API can either go into the lipid bilayer or be encapsulated in the aqueous compartment. Moreover, targeting moieties can be added to the lipid bilayer to provide a direct targeting mechanism *in vivo*.

A major benefit of liposomal drug products is that they greatly reduce the side effects that occur with non-liposomal chemotherapy treatments. In addition, liposomes promote longer blood circulation times, resulting in a longer half-life of the API. Although these therapeutics are very beneficial to patients, scalable processing and manufacturing technology platforms are still being developed.

## CURRENT MANUFACTURING METHODS

Current manufacturing methods to produce lipid-based nanoparticles include solvent injection, homogenisation and microfluidic mixing. Solvent injection methods are



Figure 1: DIANT LF system for nanoparticle synthesis, part of the DIANT production series.

typically performed by pre-mixing ethanol with a lipid and then injecting the mixture into an aqueous phase. Solvent injection methods comprise crossflow injection, static-mixers, microfluidic mixing and turbulent jet technologies, with the latter providing a highly controllable mixing strategy. Microfluidics offer a variety of mixing techniques and various geometries have been developed to mix the solvent stream with the aqueous stream.

Each of these strategies rely on different degrees of convective and diffusive forces for mixing. For example, microfluidics may mix in a very low Reynolds number state (laminar flow), whereas crossflow injection, t-mixers and turbulent jets operate at much higher Reynolds number states (turbulent flow).

## CONTINUOUS PROCESSING OF NANOPARTICLES

DIANT Pharma has introduced a series of systems that use a continuous manufacturing technology and implement a turbulent jet in co-flow. Integrated process analytical technology (PAT) provides enhanced control from particle formation throughout downstream processing, which includes ultrafiltration/diafiltration (UF/DF), purification and bioburden

“The DIANT system is a scalable, turnkey solution that uses only a single jet, producing particles from 0.2 LPM up to 100 LPM.”

reduction. The DIANT system is a scalable, turnkey solution that uses only a single jet, producing particles from 0.2 LPM up to 100 LPM (Figure 1).

The scalability of this technology is an important consideration when selecting processing equipment, from lab to commercial scale. The DIANT system has multiple modules and is offered as a continuous, closed system. The add-on modules include a buffer exchanger/concentration module, an active loading/surface modification module and a final purification stage/bioburden reduction module. The system can be a hybrid system, running in single unit operation or batch mode, or as an integrated system in an end-to-end continuous manufacturing process.

## SR-DLS for Automatic Particle Size Control

One of the PAT tools integrated in the DIANT systems is the NanoFlowSizer



Figure 2: NanoFlowSizer, an important PAT tool used to provide on-line or in-line particle size data.

(Figure 2), a spatially resolved dynamic light scattering (DLS) technology developed by InProcess-LSP (Oss, Netherlands). This PAT tool is highly useful for measuring multiple attributes

of the particles being processed, such as the Z-average (d.nm) particle size, polydispersity index (PDI), turbidity and particle size distribution (PSD). Attributes

“By using the NanoFlowSizer and DIANT system’s feedback algorithms, a highly reproducible and consistent particle size can be achieved from the beginning to the end of the processing run.”

such as the Z-average, PDI and PSD are typically listed in product specifications and may be considered critical quality attributes for liposomes and LNPs.

#### On-line Particle Size Analysis of Nanoparticles




Figure 3: Example particle size data for a 30-minute run.

Spatially Resolved DLS (SR-DLS) technology was incorporated over other DLS techniques as it enables particle size analysis at high flow rates, such that the particle size can be analysed on-line and/or in-line, as opposed to at-line or off-line. The on-line/in-line approach supports a rapid assessment of the particle size and directly measures the particles in the process stream without the nanoparticles going to waste or requiring sample handling by an operator. There is also the major benefit in that the NanoFlowSizer flow cells can be cleaned or steamed in place.

#### Enhanced Control Using the DIANT System

By measuring the particle size on-line or in-line, the particle size measurements can be used as a feedback mechanism to control the formation of the nanoparticles. When considering that nanoparticle formation is highly susceptible to process condition changes, the added layer of protection using a feedback mechanism offers much-needed quality control. Running the system for extended durations with inevitable subtle changes occurring in the local environment can impact the overall process on the nano-level. By using the NanoFlowSizer and the DIANT system’s feedback algorithms, a highly reproducible and consistent particle size can be achieved from the beginning to the end of the processing run (Figure 3).

#### Research and Development System – A Low Flow Starting Point

The DIANT LARU is a lower flow continuous processing system using the same jet technology found in the DIANT production series (Figure 4). This system is designed to have a low dead volume to reduce material costs, such as when working with costly lipids or mRNA. The DIANT LARU is offered with multiple add-ons, such as an in-line particle size module and a tangential flow filtration module.

IN 2021 WE’RE BRINGING YOU...

**BETTER CONTENT  
THAN EVER!**



## CONCLUSION

LNPs have a bright future in both the vaccine and therapeutic space. However, to make the most of their potential a scalable, high-throughput processing technology is required to move smoothly from lab to commercial scale. The DIANT system, integrated with NanoFlowSizer, provides the enhanced control required to consistently produce uniform and high-quality nanoparticles.

## ABOUT THE COMPANY

DIANT Pharma was founded in 2019. The company's proprietary continuous manufacturing technology for nanoparticles has a wide array of applications throughout multiple industries. The DIANT series systems use state-of-the-art nanoparticle processing technology, including a scalable jet that makes nanoparticle generation simple from R&D to production. DIANT Pharma is always looking for partners to broaden the use of their technology.



**Benchtop  
Continuous  
Low Flow  
Low Volumes  
Scalable  
Particle Size  
as Add-on**

Figure 4: DIANT LARU, a research and development system for nanoparticle synthesis, scalable to the DIANT production series.

## ABOUT THE AUTHOR

**Antonio Costa, PhD**, is the Chief Executive Officer of DIANT Pharma and has been involved with continuous processing of lipid and polymer nanoparticle formulations for over seven years. With his multidisciplinary background, he has been a key figure in the design and development of the continuous processing technology at the University of Connecticut (Storrs, CT, US). Dr Costa is the named inventor on two patents and multiple patent applications and the author of several peer-reviewed publications.

**MEDETECH & PHARMA  
PLATFORM**



**21 October 2021 -  
Congress Center Basel**

**Register now**

### **8th Medtech & Pharma Platform (MPP) Annual Conference: 'Achieving agility to foster innovation and bring value to patients'**

The MPP organizes the Annual Conference to provide a cross-sectoral forum to exchange knowledge, collaborate in technology and regulatory areas, as well as to promote product development and innovation. As the leading conference in Europe for products and solutions that combine medicinal product and medical device components, including devices that incorporate software, our annual event is dedicated to enhancing partnership between the pharma, medtech and tech sectors. Our audience includes experts and professionals from the pharma, medtech and tech industries as well as regulators, patients, academia and payers active in the field.

#### **Knowledge exchange**

Prominent speakers from regulatory authorities, patients' organizations, government institutions and industry share their insights across various session topics, providing insights into current and future opportunities and challenges in the development of innovative combined products.

#### **Exhibit at the platform 2021**

Showcase your company or organization to industry and regulatory professionals by becoming an Exhibitor or a Sponsor and benefit from additional presentation and networking opportunities.

#### **1-on-1 partnering**

The 1-on-1 partnering enables participants to start building new partnerships and to foster cooperation in a business-friendly environment. It is an excellent opportunity to network with many high-profile industry players.

### **About the Medtech & Pharma Platform association**

The MPP Association is a cross-sectoral not-for-profit industry association focusing on combined products. The Association comprises medtech, pharma and ICT companies dedicated to enhancing synergies between these industries. The Association aims to achieve a balanced regulatory framework for products combining medicinal product, medical device and software components to reduce time to market improve access to innovative products and better match patients' needs.

[www.medtech-pharma.com](http://www.medtech-pharma.com)